Statements (35)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
enantiomer |
| gptkbp:approvalYear |
2019
|
| gptkbp:approvedBy |
gptkb:FDA
|
| gptkbp:ATCCode |
N01AX14
|
| gptkbp:brand |
gptkb:Ketanest
gptkb:Spravato |
| gptkbp:CASNumber |
gptkb:33643-46-8
|
| gptkbp:chemicalFormula |
C13H16ClNO
|
| gptkbp:chirality |
S (sinister)
|
| gptkbp:discoveredBy |
gptkb:Calvin_Stevens
|
| gptkbp:discoveredIn |
1962
|
| gptkbp:eliminationHalfLife |
2.5-3 hours
|
| https://www.w3.org/2000/01/rdf-schema#label |
S-ketamine
|
| gptkbp:isomerOf |
R-ketamine
racemic ketamine |
| gptkbp:IUPACName |
(S)-2-(2-chlorophenyl)-2-(methylamino)cyclohexanone
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:mechanismOfAction |
NMDA receptor antagonist
|
| gptkbp:metabolism |
liver
|
| gptkbp:PubChem_CID |
gptkb:CHEMBL2103837
182137 CHEBI:61375 |
| gptkbp:routeOfAdministration |
intramuscular
intravenous nasal |
| gptkbp:sideEffect |
nausea
hallucination dissociation increased blood pressure |
| gptkbp:UNII |
690G0D6V8H
|
| gptkbp:usedFor |
treatment-resistant depression
anesthesia |
| gptkbp:bfsParent |
gptkb:Esketamine
|
| gptkbp:bfsLayer |
7
|